TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

J&J wins U.S. approval for TB tablet

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

JNJ $70.10 +$0.62

at close on MONDAY

By Anna Edney C.2012 Bloomberg News
Monday, Dec. 31, 2012, 10:30 p.m.
 

Johnson & Johnson won regulatory approval for its tuberculosis tablet Sirturo, the first drug in 40 years that provides a new way to treat the contagious lung infection.

The Food and Drug Administration cleared Sirturo to be added to therapies for use by adults whose illness is resistant to multiple medicines, the New Brunswick, N.J.- based company said Monday.

While tuberculosis was once the leading cause of death in the nation, the drug-resistant version of the illness affected about 98 people last year, according to the Centers for Disease Control and Prevention.

Subscribe today! Click here for our subscription offers.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Energy companies vie for experienced workers with skills in high demand
  2. Energy Spotlight: Adam Pope
  3. Energy-saving tactics pay off in Green Workplace Challenge
  4. Former athletes open businesses
  5. Auto review: Yaris has European flair, efficiency, affordability
  6. Password change can block hackers from wireless cameras
  7. Workarounds exist for battery woes
  8. Bank of New York Mellon 4Q earnings rise to $793 million, but revenue sluggish
  9. Beaver County power plant cleaning up spill into creek
  10. Chevron laying off 162 workers from Moon-based unit
  11. Typewriters back in style, keeping repair shops busy